Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Phase 1
Terminated
- Conditions
- Pancreatic Ductal CancerColorectal CancerAdvanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT06194877
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, United States
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorB-Raf Mutation-Related Tumors
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- MapKure, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT04249843
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Beverly Hills, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
News
No news found